Skip to main content
Premium Trial:

Request an Annual Quote

Diversa Sequences Smallest Genome to Date, Nanoarchaeum equitans

NEW YORK, Oct. 14 (GenomeWeb News) - Diversa of San Diego, along with colleagues at Yale University and Celera Genomics, have published an analysis of the genome sequence and annotation of the smallest genome discovered to date, Nanoarchaeum equitans, which weighs in at under 500 kilobases. 

The paper, titled "The genome of Nanoarchaeum equitans: Insights into early archaeal evolution and derived parasitism" will be available at the Proceedings of the National Academy of Scienceswebsite later this week.

N. equitans is a hyperthermophilic archaeon and the only known archaeal parasite, according to Diversa. It was discovered in a submarine hydrothermal vent in the Kolbeinsey ridge, north of Iceland.

Analysis of the tiny genome sequence -- which lacks the genes for central metabolism, primary biosynthesis, and bioenergetic apparatus -- provided insight into the simplest known metabolism required by an organism for survival, according to the research team. In addition, the presence of reverse gyrase enzymes, which are found only in N. equitans and other hyperthermophiles, "indicates that the evolution of these organisms was an early event and supports the hypothesis of a hot primeval earth," Diversa said.

Diversa has retained the rights to commercial applications of the organism. The company said that engineered organisms like N. equitans would have applications as biotransformations, as biosensors, for pharmaceutical synthesis, or for biodefense. 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.